Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier

Brain Research

Volumn 987, Issue 1, 2003, Pages 39-48

  Boules, Mona ^a   McMahon, Beth ^a   Wang, Rui ^a   Warrington, Lewis ^a   Stewart, Jennifer ^a   Yerbury, Sally ^a   Fauq, Abdul ^a   McCormick, Daniel ^b   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Apomorphine; Cocaine; D Amphetamine; Haloperidol; NT69L

Indexed keywords

APOMORPHINE; COCAINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR; GLUCOSE; HALOPERIDOL; HYDROCORTISONE; NEUROTENSIN DERIVATIVE; NT 69 L; THYROXINE; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICATALEPTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CATALEPSY; CLIMBING; COLD TOLERANCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; GLUCOSE BLOOD LEVEL; HYDROCORTISONE BLOOD LEVEL; HYPERACTIVITY; HYPOTHERMIA; INJECTION; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; THYROXINE BLOOD LEVEL;

EID: 0142106466     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)03227-X     Document Type: Article

References (38)

1. Bissette G., Nemeroff C.B., Loosen P.T., Prange A.J., Lipton M.A. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature. 262:1976;607-609.
2. Boules M., Cusack B., Zhao L., Fauq A., McCormick D.J., Richelson E. A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents. Brain Res. 865:2000;35-44.
3. Boules M., Warrington L., Fauq A., McCormick D., Richelson E. Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats. Eur. J. Pharmacol. 428:2001;227-233.
4. Boules M., Warrington L., Fauq A., McCormick D., Richelson E. A novel neurotensin analog blocks cocaine- and D-amphetamine-induced hyperactivity. Eur. J. Pharmacol. 426:2001;73-76.
5. Carraway R., Leeman S.E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 248:1973;6854-6861.
6. Checler F., Vincent J.P., Kitabgi P. Neurotensin analogs [D-TYR11] and [D-PHE11]neurotensin resist degradation by brain peptidases in vitro and in vivo. J. Pharmacol. Exp. Ther. 227:1983;743-748.
7. Cusack B., Boules M., Tyler B.M., Fauq A., McCormick D.J., Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Res. 856:2000;48-54.
8. Donato di Paola E., Cusack B., Yamada M., Richelson E. Desensitization and downregulation of neurotensin receptors in murine neuroblastoma clone N1E-115 by [D-Lys8] neurotensin(8-13). J. Pharmacol. Exp. Ther. 264:1993;1-5.
9. Drumheller A.D., Gagne M.A., St-Pierre S., Jolicoeur F.B. Effects of neurotensin on regional brain concentrations of dopamine, serotonin and their main metabolites. Neuropeptides. 15:1990;169-178.
10. Dubuc I., Pain C., Suaudeau C., Costentin J. Tolerance to the hypothermic but not to the analgesic effect of [D-Trp11]neurotensin during the semichronic intracerebroventricular infusion of the peptide in rats. Peptides. 15:1994;303-307.
11. Fuxe K., Agnati L.F. Receptor-receptor interactions in the central nervous system. A new integrative mechanism in synapses. Med. Res. Rev. 5:1985;441-482.
12. Fuxe K., O'Connor W.T., Antonelli T., Osborne P.G., Tanganelli S., Agnati L.F., Ungerstedt U. Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum. Proc. Natl. Acad. Sci. USA. 89:1992;5591-5595.
13. Gilbert J.A., Strobel T.R., Richelson E. Desensitization of neurotensin receptor-mediated cyclic GMP formation in neuroblastoma clone N1E-115. Biochem. Pharmacol. 37:1988;2833-2838.
14. Hertel P., Byskov L., Didriksen M., Arnt J. Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity. Eur. J. Pharm. 422:2001;77-81.
15. Jolicoeur F.B., Barbeau A., Rioux F., Quirion R., St-Pierre S. Differential neurobehavioral effects of neurotensin and structural analogues. Peptides. 2:1981;171-175.
16. Kinkead B., Binder E.B., Nemeroff C.B. Does neurotensin mediate the effects of antipsychotic drugs? Biol. Psychiatry. 46:1999;340-351.
17. Li X.M., Ferraro L., Tanganelli S., O'Connor W.T., Hasselrot U., Ungerstedt U., Fuxe K. Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study. J. Neural Transm. Gen. Sect. 102:1995;125-137.
18. Malendowicz L.K., Miskowiak B. Effects of prolonged administration of neurotensin, arginine-vasopressin, NPY, and bombesin on blood TSH, T3 and T4 levels in the rat. In Vivo. 4:1990;259-261.
19. Nemeroff C.B., Bissette G., Prange A.J., Loosen P.T., Barlow T.S., Lipton M.A. Neurotensin: central nervous system effects of a hypothalamic peptide. Brain Res. 128:1977;485-496.
20. Nemeroff C.B., Hernandez D.E., Luttinger D., Kalivas P.W., Prange A.J. Interactions of neurotensin with brain dopamine systems. Ann. NY Acad. Sci. 400:1982;330-344.
21. Nemeroff C.B., Levant B., Myers B., Bissette G. Neurotensin, antipsychotic drugs, and schizophrenia. Basic and clinical studies. Ann. NY Acad. Sci. 668:1992;146-156.
22. Nicot A., Berod A., Gully D., Rowe W., Quirion R., de Kloet E.R., Rostene W. Blockade of neurotensin binding in the rat hypothalamus and of the central action of neurotensin on the hypothalamic-pituitary-adrenal axis with nonpeptide receptor antagonists. Neuroendocrinology. 59:1994;572-578.
23. Pardridge W.M. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 70:1998;1781-1792.
24. Rinkel G.J., Hoeke E.C., van Wimersma Greidanus T.B. Elective tolerance to behavioral effects of neurotensin. Physiol. Behav. 31:1983;467-470.
25. Rowe W., Viau V., Meaney M.J., Quirion R. Central administration of neurotensin stimulates hypothalamic-pituitary-adrenal activity. The paraventricular CRF neuron as a critical site of action. Ann. NY Acad. Sci. 668:1992;365-367.
26. Sarret P., Gendron L., Kilian P., Nguyen H.M., Gallo-Payet N., Payet M.D., Beaudet A. Pharmacology and functional properties of NTS2 neurotensin receptors in cerebellar granule cells. J. Biol. Chem. 277:2002;36233-36243.
27. Scatton B. Differential regional development of tolerance to increase in dopamine turnover upon repeated neuroleptic administration. Eur. J. Pharmacol. 46:1977;363-369.
28. Scatton B., Glowinski J., Julou L. Dopamine metabolism in the mesolimbic and mesocortical dopaminergic systems after single or repeated administrations of neuroleptics. Brain Res. 109:1976;184-189.
29. Scatton B., Thierry A.M., Glowinski J., Julou L. Effects of thioproperazine and apomorphine on dopamine synthesis in the mesocortical dopaminergic systems. Brain Res. 88:1975;389-393.
30. See R.E. Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride. Neurosci. Lett. 129:1991;265-268.
31. Tyler B.M., Douglas C.L., Fauq A., Pang Y.P., Stewart J.A., Cusack B., McCormick D.J., Richelson E. In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier. Neuropharmacology. 38:1999;1027-1034.
32. Ushijima I., Carino M.A., Horita A. Involvement of D1 and D2 dopamine systems in the behavioral effects of cocaine in rats. Pharmacol. Biochem. Behav. 52:1995;737-741.
33. Vincent J.P., Mazella J., Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol. Sci. 20:1999;302-309.
34. Von Euler G., Fuxe K. Neurotensin reduces the affinity of D-2 dopamine receptors in rat striatal membranes. Acta Physiol. Scand. 131:1987;625-626.
35. von Euler G., Fuxe K., Benfenati F., Hansson T., Agnati L.F., Gustafsson J.A. Neurotensin modulates the binding characteristics of dopamine D2 receptors in rat striatal membranes also following treatment with toluene. Acta Physiol. Scand. 135:1989;443-448.
36. von Euler G., Meister B., Hokfelt T., Fuxe K. Intraventricular injection of neurotensin reduces the binding of dopamine D-2 receptors in the rat forebrain. Acta Physiol. Scand. 137:1989;309-310.
37. von Euler G., van der Ploeg I., Fredholm B.B., Fuxe K. Neurotensin decreases the affinity of dopamine D2 agonist binding by a G protein-independent mechanism. J. Neurochem. 56:1991;178-183.
38. Yamada M., Richelson E. Further characterization of neurotensin receptor desensitization and downregulation in clone N1E-115 neuroblastoma cells. Biochem. Pharmacol. 45:1993;2149-2154.